Management of hypertension in overweight and obese patients: A practical guide for clinicians

Current Hypertension Reports

Volumn 7, Issue 5, 2005, Pages 330-336

  Dentali, Francesco ^a   Sharma, Arya M ^a   Douketis, James D ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENZPHETAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; CILNIDIPINE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; LISINOPRIL; MANIDIPINE; METHYLDOPA; MOXONIDINE; PHENDIMETRAZINE; PLACEBO; PRAZOSIN; SIBUTRAMINE; SODIUM CHLORIDE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BODY MASS; CARBOHYDRATE INTAKE; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; DYSLIPIDEMIA; FOLLOW UP; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HEALTH PROGRAM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID ABSORPTION; LIPOLYSIS; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT COURSE THERAPY; SIDE EFFECT; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASODILATATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 27544490136     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0065-5     Document Type: Review

References (45)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288:1723-1727.
2. World Health Organization: Controlling the global obesity epidemic. http:/www.who.int/nut/obs.htm. Accessed March 2, 2005.
3. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
4. Must A, Spadano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523-1529.
5. Sharma AM, Engeli S, Pischon T: New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertens Rep 2001, 3:152-156.
6. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855-1867.
7. Stevens VJ, Obarzanek E, Cook NR, et al.: Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. The Hypertension Prevention Research Group. Ann Intern Med 2001, 134:1-11
8. National Institutes of Health, National Heart, Lung and Blood Institute, Obesity Education Initiative: Clinical Guidelines on the identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 1998.
9. Rippe JM, Crossley S, Ringer R: Obesity as a chronic disease: modern medical and lifestyle management. J Am Diet Assoc 1998, 98(10 Suppl 2):S9-S15.
10. Serdula MK, Mokdad AH, Williamson DE, et al.: Prevalence of attempting weight loss and strategies for controlling weight. JAMA 1999, 282:1353-1358.
11. Dansinger ML, Gleason JA, Griffith JL, et al.: Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005, 293:43-53.
12. Foster GD, Wyatt HR, Hill JO, et al.: A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003, 348:2082-2090.
13. Stern L, Iqbal N, Seshadri P, et al.: The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004, 140:778-785.
14. Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al.: Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000, 8:399-402.
15. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. Finnish Diabetes Prevention Study Group. N Engl J Med 2001, 344:1343-1350.
16. Stamler R, Stamler J, Grimm R, et al.: Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial - the Hypertension Control Program. JAMA 1987, 257:1484-1491.
17. Whelton PK, Appel LJ, Espeland MA, et al.: Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998, 279:839-846.
18. Metz JA, Stern JS, Kris-Etherton P, et al.: A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000, 160:2150-2158.
19. Yanovski SZ, Yanovski JA: Obesity. N Engl J Med 2002, 346:591-602.
20. Bakris G, Calhoun D, Egan B, et al.: Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Orlistat and Resistant Hypertension Investigators. J Hypertens 2002, 20:2257-2267.
21. Lindgärde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000, 248:245-254.
22. Sharma AM, Golay A: Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002, 20:1873-1878.
23. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to life-style changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161.
24. McMahon FG, Fujioka K, Singh BN, et al.: Efficacy and safety of sibutramine in obese white and African-American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000, 160:2185-2191.
25. McMahon FG, Weinstein SP, Rowe E, et al.: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Sibutramine in Hypertensives Clinical Study Group. J Hum Hypertens 2002, 16:5-11.
26. Derosa G, Cicero AF, Murdolo G, et al.: Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005, 7:47-55.
27. Lloyd-Jones DM, Evans JC, Larson MG, et al.: Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594-599.
28. Bramlage F, Pittrow D, Wittchen HU, et al.: Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904-910.
29. Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 41:1178-1179.
30. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
31. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507-1513.
32. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868-873.
33. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
34. Grassi G, Seravalle G, Dell'Oro R, et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761-1769.
35. Stein PP, Black HR: Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991, 14:425-448.
36. Ueshiba H, Miyachi Y: Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003, 35:532-536.
37. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415-420.
38. CIBIS-2 study group: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
39. Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and clinidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 2004, 43:561-565.
40. White WB, Elliott WJ, Johnson ME, Black HR: Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. J Hum Hypertens 2001, 15:135-141.
41. Tarif N, Bakris GL: Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997, 12:2244-2250.
42. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
43. Reaven GM, Clinkingbeard C, Jeppesen J, et al.: Comparison of the hemodynamic and metabolic effects of low dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995, 8(5 Pt 1):461-466.
44. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
45. Takahashi H, Nishikawa T, Mizutani T, Handa F: Oral clonidine premedication decreases energy expenditure in human volunteers. Can J Anaesth 1997, 44:268-272.